An outline of various approaches to vaccine development that are in earlier phase research, e.g., phase I or II trials; development pathways for these candidates are uncertain at this time.
Vaccine Approaches in Early-Phase Development
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.
Px Wire April-June 2017, Vol. 10, No. 2
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, offers an advocate’s guide to some new types of biomedical prevention trial designs. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
An Advocate’s Guide to Research Terms in the Post-Placebo Era
In Px Wire, AVAC’s quarterly update on HIV prevention design, we presented this illustration on some new types of biomedical prevention trial design. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
To download just the graphic, without the accompanying text and lexicon, click here: JPG, PDF. For the lexicon only, click here (PDF).
Regulatory Status of TDF/FTC for PrEP
A global snapshot of the regulatory status of oral PrEP by country. JPEG and PPT versions available here.
AIDS Vaccine Science for Busy Advocates: Antibody Research
A primer on antibodies and their role in HIV prevention research. Read on for a glossary of relevant terms and to learn how broadly neutralizing antibodies may be important to the development of a vaccine.
What Is Up With DMPA And “Grades” For Family Planning?
AVAC’s sheet on the hormonal contraceptive known as Depo-Provera (DMPA) and the WHO grading system for contraceptives explains key issues in plain language. Research findings have raised questions about the safety and effectiveness of DMPA for women who face a high risk of HIV. WHO evaluates the safety and efficacy of contraceptive methods.
Global Investments in Multipurpose Prevention Technology Research and Development
CAMI Health and the Resource Tracking for HIV Prevention Research and Development Working Group published this 2016 analysis of investment through grants in multipurpose prevention technology. Read on for statistics showing increased funding overall, and review research and development progress to date.
Px Wire January-March 2017, Vol. 10, No. 1
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, looks ahead at a host of issues we are watching in 2017. Are we confronting “Fast Track” goals with the sober analysis they demand? Will oral PrEP guidelines translate into programs and will programs meet people’s needs? What progress can we expect from studies on the dapivirine vaginal ring, various vaccine candidates or on broadly neutralizing antibodies, which are garnering so much press attention of late? Will global leaders embrace policies that ensure data gaps on key populations will finally be filled?
End-User Research Landscape Mapping & Findings
The HIV Prevention Market Manager undertook an effort to map the landscape of ongoing and planned work on HIV prevention and adolescent girls and young women and other populations in sub-Saharan Africa. This document provides a summary and analysis of the end-user projects and studies underway in order to inform collaborations and identify gaps and next steps in research.